Endophthalmitis Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Neovascular Age-Related Macular Degeneration

REFERENCES

• Aiello LP, et al. Evolving guidelines for intravitreous injections. Retina, 2004; 24(5 Suppl):S3–19.
   Google Scholar
• Jager RD, et al. Risks of intravitreous injection: A comprehensive review. Retina, 2004; 24(5):676–98.
   PubMedGoogle Scholar
• Jonas JB. Intravitreal triamcinolone acetonide: A change in a paradigm. Ophthalmic Res, 2006; 38(4):218–45.
   PubMedGoogle Scholar
• Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand, 2005; 83(6):645–63.
   PubMedGoogle Scholar
• Jonas JB, Kamppeter B. Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty. Cornea, 2006; 25(2):240–1.
   PubMedGoogle Scholar
• Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res, 2005; 24(5):587–611.
   PubMedGoogle Scholar
• Jonas JB, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology, 2005; 112(4):593–8.
   PubMedGoogle Scholar
• Jonas JB, Kreissig I, and Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol, 2003; 136(2):384–6.
   PubMedGoogle Scholar
• Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol, 2001; 132(3):425–7.
   PubMedGoogle Scholar
• Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology, 2003; 110(8):1517–25.
   PubMedGoogle Scholar
• Brown DM, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology, 2009; 116(1):57–65 e5.
   Google Scholar
• D’Amico DJ, et al. Pegaptanib sodium for neovascular age-related macular degeneration: Two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology, 2006; 113(6):992–1001 e6.
   Google Scholar
• Gragoudas ES, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 2004; 351(27):2805–16.
   PubMed Web of Science ®Google Scholar
• Heier JS, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study. Ophthalmology, 2006; 113(4):633 e1-4.
   Google Scholar
• Regillo CD, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol, 2008; 145(2):239–248.
   PubMedGoogle Scholar
• Rosenfeld PJ, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006; 355(14):1419–31.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging, 2005; 36(4):331–5.
   PubMedGoogle Scholar
• Schwartz SG, Flynn HW, Scott IU. Endophthalmitis after intravitreal injections. Expert Opin Pharmacother, 2009; 10(13):2119–26.
   PubMedGoogle Scholar
• Michels S, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology, 2005; 112(6):1035–47.
   PubMedGoogle Scholar
• Moshfeghi AA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology, 2006; 113(11):2002 e1-12.
   PubMedGoogle Scholar
• Avery RL, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology, 2006; 113(3):363–372 e5.
   Google Scholar
• Gregori NZ, et al. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina, 2008; 28(9): 1325–37.
   PubMedGoogle Scholar
• Gregori NZ, et al. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina, 2009; 29(7):913–25.
   PubMedGoogle Scholar
• Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging, 2005; 36(4):336–9.
   PubMedGoogle Scholar
• Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol, 2009; 20(3): 158–65.
   PubMedGoogle Scholar
• Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol, 2009; 20(3):166–74.
   PubMedGoogle Scholar
• Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol, 2009; 54(3):372–400.
   PubMedGoogle Scholar
• Brown DM, et al. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology, 2010; 117(6):1124–1133 e1.
   Google Scholar
• Campochiaro PA, et al. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology, 2010; 117(6):1102–1112 e1.
   Google Scholar
• Jeganathan VS. Anti-angiogenesis drugs in diabetic retinopathy. Curr Pharm Biotechnol, 2011;12(3):369–72.
   PubMedGoogle Scholar
• Amato JE, et al. Steroid hypopyon following intravitreal triamcinolone acetonide injection in a pseudophakic patient. Ocul Immunol Inflamm, 2005; 13(2-3):245–7.
   PubMedGoogle Scholar
• Chen SD, et al. Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema. Br J Ophthalmol, 2004; 88(6): 843–4.
   PubMedGoogle Scholar
• Moshfeghi AA, et al. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol, 2004; 138(3):489–92.
   PubMedGoogle Scholar
• Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol, 2003; 87(8):972–4.
   PubMedGoogle Scholar
• Bakri SJ et al. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol, 2008; 246(7):955–8.
   PubMedGoogle Scholar
• Cunningham ET et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology, 2005; 112(10):1747–57.
   PubMedGoogle Scholar
• Elman MJ, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology, 2010; 117(6):1064–1077 e35.
   PubMedGoogle Scholar
• Brown DM, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med, 2006; 355(14):1432–44.
   PubMedGoogle Scholar
• Boyer DS, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology, 2009; 116(9): 1731–9.
   PubMedGoogle Scholar
• Aggio FB, et al. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye (Lond), 2007; 21(3):408–9.
   PubMedGoogle Scholar
• Alkuraya HS, et al. Acute endophthalmitis caused by Staphylococcus lugdunesis after intravitreal bevacizumab (Avastin) injection. Int Ophthalmol, 2009; 29(5):411–3.
   PubMedGoogle Scholar
• Cavalcante LL, et al. Intravitreal injection analysis at the Bascom Palmer Eye Institute: Evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol, 2010; 4:519–24.
   PubMedGoogle Scholar
• Chen E, et al. Streptococcus mitis endophthalmitis presenting as frosted branch angiitis after intravitreal pegaptanib sodium injection. Ophthalmic Surg Lasers Imaging, 2009; 40(2):192–4.
   PubMedGoogle Scholar
• Diago T, et al. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina, 2009; 29(5):601–5.
   PubMedGoogle Scholar
• Fintak DR, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina, 2008; 28(10):1395–9.
   PubMedGoogle Scholar
• Georgopoulos M, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol, 2009; 93(4):457–62.
   PubMedGoogle Scholar
• Jonas JB, Spandau UH, and Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye (Lond), 2008; 22(4):590–1.
   PubMedGoogle Scholar
• Klein KS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology, 2009; 116(6): p. 1225 e1.
   Google Scholar
• Lee SH, et al. Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab. Eye (Lond), 2010; 24(2):226–32.
   PubMedGoogle Scholar
• Mason JO 3rd, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina, 2008; 28(4):564–7.
   PubMedGoogle Scholar
• Mezad-Koursh D, et al. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina, 2010; 30(7):1051–7.
   PubMedGoogle Scholar
• Pilli S, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol, 2008; 145(5):879–82.
   PubMedGoogle Scholar
• Wickremasinghe SS, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology, 2008; 115(11):1911–5.
   PubMedGoogle Scholar
• Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol, 2008; 246(5):779–81.
   PubMedGoogle Scholar
• Bakri SJ, et al. Bilateral simultaneous intravitreal injections in the office setting. Am J Ophthalmol, 2009; 148(1):66-9 e1.
   PubMedGoogle Scholar
• Lima LH, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina, 2009; 29(9):1213–7.
   PubMedGoogle Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol, 2006; 90(11):1344–9.
   PubMedGoogle Scholar
• Bakri SJ, et al. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina, 2009; 29(5):573–8.
   PubMedGoogle Scholar
• Forte R, et al. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration. Ophthalmic Res, 2010; 45(3):129–134.
   PubMedGoogle Scholar
• Yip PP, et al. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol, 2009; 93(6):754–8.
   PubMedGoogle Scholar
• Stewart JM, et al. Bacterial contamination of needles used for intravitreal injections: A prospective, multicenter study. Ocul Immunol Inflamm, 2011; 19(1): 32–8.
   PubMedGoogle Scholar